Verition Fund Management
RPRX icon

Verition Fund Management’s Royalty Pharma RPRX Stock Holding History

Verition Fund Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,500
Closed -$265K – 3881
2025
Q3 		$265K Buy
+7,500
New +$272K ﹤0.01% 3356

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Verition Fund Management's RPRX Position: Q1 2026 in Review

Verition Fund Management sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 95,068 shares — an estimated $3.67M sold.

Verition Fund Management first reported a position in RPRX in Q1 2021 and held it in 19 quarters. The position peaked at $10.6M in Q3 2025. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Verition Fund Management reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 95,068 Royalty Pharma shares in Q1 2026, an estimated $3.67M.
  • Verition Fund Management first reported a position in Royalty Pharma in Q1 2021 and held it in 19 quarters.
  • Verition Fund Management's Royalty Pharma position peaked at $10.6M in Q3 2025.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.